| Literature DB >> 20653976 |
Hsin-Yao Cheng1, Yi-Fong Chen, Hwei-Ling Peng.
Abstract
BACKGROUND: The cationic peptide antibiotic polymyxin has recently been reevaluated in the treatment of severe infections caused by gram negative bacteria.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20653976 PMCID: PMC2919465 DOI: 10.1186/1423-0127-17-60
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
Bacterial strains and plasmids used in this study
| Strain or plasmid | Description | Reference or source |
|---|---|---|
| Strains | ||
| | ||
| CG43S3 | CG43 Smr | [ |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | [ |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | [ |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| Δ | CG43S3Δ | This study |
| | ||
| S17-1λ | [ | |
| XL1-Blue MRF' Kan | Δ( | Stratagene |
| BL21(DE3) | F- | Novagen |
| Plasmids | ||
| yT&A | T/A-type PCR cloning vector, Apr | Yeastern |
| pET30b | His-tagged protein expression vector, Kmr | Novagen |
| pBT | Bait plasmid, | Stratagene |
| pTRG | Target plasmid, | Stratagene |
| pBT-LGF2 | Control plasmid containing a fragment encoding the yeast transcriptional activator Gal4 fused with λ-cI, Cmr | Stratagene |
| pTRG-GAL11P | Control plasmid containing a fragment encoding a mutant form of Gal11 protein, called Gal11P, fused with RNAPα, Tcr | Stratagene |
| pKAS46 | Suicide vector, | [ |
| pRK415 | Shuttle vector, | [ |
| placZ15 | promoter selection vector, | [ |
| pRK415-PmrF | 1.3-kb fragment containing a | This study |
| pRK415-RcsB | 1.2-kb fragment containing the entire rcsB locus cloned into pRK415, Tcr | [ |
| pRK415-PmrA | 1.1-kb fragment containing a | This study |
| pRK415-PhoP | 900-bp fragment containing a | This study |
| pRK415-PmrD | 550-bp fragment containing a | This study |
| placZ15-PpmrH | 500-bp fragment containing the upstream region of the | This study |
| placZ15-PpmrD | 350-bp fragment containing the upstream region of the | This study |
| pET30b-PhoP | 711-bp fragment encoding full-length PhoP cloned into pET30b, Kmr | This study |
| pET30b-PhoPN | 447-bp fragment encoding residues 1-149 of PhoP cloned into pET30b, Kmr | This study |
| pET30b-PmrBC | 828-bp fragment encoding residues 90-365 of PmrB cloned into pET30b, Kmr | This study |
| pET-PmrA | 669-bp fragment encoding full-length PmrA cloned into pET29b, Kmr | This study |
| pET-PmrD | 243-bp fragment encoding full-length PmrD cloned into pET29b, Kmr | This study |
| pBT-PmrA | 669-bp fragment encoding full-length RcsB cloned into pBT, Cmr | This study |
| pTRG-PmrD | 243-bp fragment encoding full-length RcsA cloned into pTRG, Tcr | This study |
Oligonucleotide primers used in this study
| Primer | Enzyme cleaved | Complementary position | |
|---|---|---|---|
| ppmrF01 | 5'-GATGGAAAAGCTGAAGGCGATGG-3' | None | -161 relative to the |
| ppmrF02 | 5'-CAGC | +1116 relative to the | |
| pmrA06 | 5'-GAG | +682 relative to the | |
| pmrAp03 | 5'-CAATT | -424 relative to the | |
| phoP01 | 5'-CGCTCGCCGTTC | -171 relative to the | |
| phoP02 | 5'-GCAAC | +729 relative to the | |
| pmrDe02 | 5'-C | +250 relative to the | |
| pmrDp01 | 5'-T | -278 relative to the | |
| pmrDp02 | 5'-CGCAC | +75 relative to the | |
| pmrHp01 | 5'-TCT | -425 relative to the | |
| pmrHp02 | 5'-CTT | +34 relative to the | |
| phoP05 | 5'-GTAATGACAGCGGGAAGATATG-3' | None | +753 relative to the |
| phoP06 | 5'-CAGCCGTTTATATTTTGCGT-3' | None | -25 relative to the |
| pmrBe03 | 5'-T | +283 relative to the | |
| pmrBe04 | 5'-C | +1095 relative to the | |
| KP1760-1 | 5'-GGAATTC | +1 relative to the | |
| KP1760-2 | 5'-CCG | +672 relative to the | |
| KP3573-1 | 5'-GGAATTC | +1 relative to the | |
| KP3573-2 | 5'-CCG | +243 relative to the | |
| pmrA10 | 5'-A | +1 relative to the | |
| pmrA11 | 5'-AAT | +672 relative to the | |
| pmrDe15 | 5'-AAA | +1 relative to the | |
| pmrDe16 | 5'-TTT | +243 relative to the |
a The nucleotide sequence recognized by each restriction enzyme listed are in bold text.
Figure 1Deletion effects of . (A) Comparison of colony morphology. The K. pneumoniae strains were streaked on an LB agar plate, incubated at 37°C overnight and photographed. (B) Sedimentation test. The strains were cultured overnight in LB broth at 37°C and subjected to centrifugation at 4,000 ×g for 5 min. Quantification of K2 CPS amounts of each strain is shown below the figure. Values are shown as averages ± standard deviations from triplicate samples. (C) Polymyxin resistance assay. The log-phased cultures of K. pneumoniae CG43S3, Δugd, Δwza or ΔrcsB mutants were challenged with 1 or 2 units/ml of polymyxin B. (D) Polymyxin resistance assay. The log-phased culture of K. pneumoniae strains were challenged with 2 or 4 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. *, P < 0.01 compared to the parental strain CG43S3. **, P < 0.01 compared to each strain carrying pRK415.
Figure 2Involvement of . (A) The log-phased cultures of K. pneumoniae CG43S3, the ΔpmrF mutant or ΔpmrF carrying pRK415-PmrF were grown in LB or LB supplemented with 1 mM Fe3+ and then challenged with 2 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. (B) The survival rates of K. pneumoniae CG43S3ΔrcsB, the isogenic ΔpmrFΔrcsB mutant, and ΔpmrFΔrcsB mutant strain carrying the complementation plasmid pRK415-PmrF within the mouse macrophage RAW264.7 were determined. The results shown are relative survival rates which were calculated from the viable colony counts of intracellular bacteria divided by individual original inoculums. Values are shown as the average of five replicas. Error bars, standard deviations. *, P < 0.01 compared to each parental strain; **, P < 0.01 compared to each mutant strain carrying pRK415-PmrF.
Figure 3Effects of . (A) The log-phased cultures of K. pneumoniae CG43S3, the ΔpmrA, ΔpmrD or ΔphoP mutants were grown in LB, LB supplemented with 10 mM Mg2+ or LB supplemented with 1 mM Fe3+ and then challenged with 2 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. (B) The log-phased cultures of K. pneumoniae CG43S3 carrying pRK415, the ΔpmrAΔphoP mutant strains carrying pRK415, pRK415-PhoP or pRK415-PmrA were grown in LB and challenged with 2 units/ml of polymyxin B. The survival rates are shown as the average ± standard deviations from triplicate samples. (C) The survival rates of K. pneumoniae CG43S3ΔrcsB, the isogenic ΔpmrAΔrcsB, ΔphoPΔrcsB and ΔpmrDΔrcsB mutants, and each mutant strain carrying the complementation plasmids pRK415-PmrA, pRK415-PhoP or pRK415-PmrD within the mouse macrophage RAW264.7 were determined. The results shown are relative survival rates which were calculated from the viable colony counts of intracellular bacteria divided by individual original inoculums. Values are shown as the average of five replicas. Error bars, standard deviations. *, P < 0.01 compared to each parental strain; **, P < 0.01 compared to each mutant strain carrying the complementation plasmid.
Figure 4Schematic representation of . (A) Diagrammatic representation of the pmrH and pmrD loci. The large arrows represent the open reading frames. The relative positions of the primer sets used in PCR-amplification of the DNA fragments encompassing the Pand Pregions are indicated, and the numbers denote the relative positions to the translational start site. The name and approximate size of the DNA probes used in electro-mobility shift assay (EMSA) are shown on the left. The dashed boxes indicate the predicted PhoP and PmrA binding sequences and the alignment result is shown below. The identical nucleotide sequences are underlined. HP, hypothetical protein. (B) The β-galactosidase activities of log-phased cultures of K. pneumoniae strains carrying placZ15-PpmrH grown in LB, LB containing 10 mM MgCl2, LB containing 0.1 mM FeCl3 or 0.1 mM FeCl3 plusing 0.3 mM deferoxamine were determined and expressed as Miller units. (C) The β-galactosidase activities of log-phased cultures of K. pneumoniae strains carrying placZ15-PpmrD grown in LB, LB containing 10 mM MgCl2 or LB containing 0.1 mM FeCl3 were determined and expressed as Miller units. The data shown were the average ± standard deviations from triplicate samples. *, P < 0.01 compared to the same strain grown in LB medium. **, P < 0.01 compared to the parental strain grown in LB medium. #, P < 0.01 compared to the parental strain grown in LB medium supplemented with ferric ions.
Figure 5Binding of His-PhoP and His-PhoP. (A) Specific binding of recombinant His-PhoP protein to the putative pmrD promoter. EMSA was performed by using the 32P-labeled DNA probe of Pincubated with increasing amounts of the His-PhoP (lanes 2 to 5), with 40 pmole of His-PhoP plus increasing amounts of the unlabeled PDNA (specific competitor, lane 6 to 9), or with excess amounts of non-specific competitor DNA (lane 10 and 11). The amounts of recombinant proteins and DNA probes used are indicated in the figure. (B) EMSA was performed with 0, 4 or 40 pmole of His-PhoP (lanes 1 to 3), His-PhoPN149 (lanes 4 to 6) or 100 pmole of BSA (lane 7). The arrows indicate the PhoP/Pcomplex and free probe of P.
Figure 6. (A) Bacterial two-hybrid analysis of PmrD/PmrA interaction in vivo. The E. coli XL1-Blue cells co-transformed with various combinations of pTRG and pBT-derived plasmids were diluted serially and spotted onto the indicator plate. The bacterial growth after 36 h was investigated and photographed. Combinations of plasmids carried by each strain were indicated above the figure. (B) Klebsiella PmrD prevents the dephosphorylation of PmrA by its cognate sensor protein. The phosphorylation state of the recombinant His-PmrA protein was monitored upon the addition of the sensor protein His-PmrBC276 in the presence (PmrD) or absence (-) of purified His-PmrD protein at specific time points as indicated. The arrows indicate phospho-PmrA (P-PmrA) and phospho-PmrBC276 (P-PmrBC276). (C) Kinase/phosphatase assay was carried out using the recombinant His-PmrA (final concentration 5 μM) and His-PmrBC276 (final concentration 2.5 μM) in the presence (PmrD) or absence (-) of the recombintant His-PmrD protein (final concentration 5 μM). The small cationic proteins RNase A and cytochrome C were introduced individually as a negative control at a final concentration of 5 μM. (D) Autokinase assay of the recombinant His-PmrBC276 (final concentration 2.5 μM) was performed in the presence (PmrD) or absence (-) of the recombintant His-PmrD protein (final concentration 5 μM).